| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 115.93 | 8.7% | 18.3% |
| Total Income | 115.93 | 8.7% | 18.3% |
| Expenditure | 118.92 | 19.6% | 5.4% |
| PBT | -0.51 | 103.8% | 94.7% |
| Net Profit | -0.81 | 106.3% | 92.1% |
| OPM | -2.58% | 9.41pp | 12.60pp |
| NPM | -0.70% | 12.86pp | 9.82pp |
| EPS | -0.02 | 107.7% | 90.0% |
Immunocore Reports Q2 2026 Results: KIMMTRAK Net Revenues Reach $115.9M, Up 18% YoY
06 Aug 2026 · 6 Aug, 4:37 pm
Summary
Immunocore Holdings plc announced its financial results for the second quarter and first half of 2026, highlighting strong performance driven by KIMMTRAK. KIMMTRAK net revenues grew 18% year-over-year to $115.9 million in Q2 2026. The company achieved a net income of $12.2 million for the first half of 2026, a substantial turnaround from a net loss in the prior year. Significant progress was noted in clinical trials, including the nearing completion of enrollment for the Phase 3 TEBE-AM trial and promising survival data for KIMMTRAK. The company ended the quarter with a robust cash position of $880.2 million.
Key Highlights
- 1
KIMMTRAK net revenues reached $115.9 million in Q2 2026, an increase of 18% year-over-year.
- 2
For the first half of 2026, net income was $12.2 million, a significant improvement from a net loss of $5.3 million in the same period of 2025.
- 3
Enrollment in the Phase 3 TEBE-AM trial for advanced cutaneous melanoma is nearing its target of 540 patients, with data potentially available by the end of 2026.
- 4
Five-year overall survival data for KIMMTRAK showed it doubled the likelihood of patients with metastatic uveal melanoma being alive at five years.
- 5
Cash, cash equivalents, and marketable securities stood at $880.2 million as of June 30, 2026.
- 6
Phase 1b data presented at ASCO showed promising clinical activity for brenetafusp monotherapy in heavily pretreated advanced melanoma patients.
Management Comments
Bahija Jallal
The five-year overall survival data for KIMMTRAK underscores the lasting impact of our medicine for patients with metastatic uveal melanoma and reinforces our confidence in the potential of our platform. With enrollment in our Phase 3 TEBE-AM trial nearing target completion and continued progress across our pipeline, we remain focused on our mission: delivering innovative transformative medicines to improve outcomes for patients with serious diseases.
Informational and educational content only. Not investment advice.